Effects of Memantine on Event-related Potential in the Comparison of Patients With Early Schizophrenia and Healthy Subjects
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
Price : $35 *
At a glance
- Drugs Memantine (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 11 Dec 2015 Planned end date changed from 1 Sep 2015 to 1 Dec 2016, as reported by ClinicalTrials.gov.
- 11 Dec 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Dec 2016, as reported by ClinicalTrials.gov.
- 11 Sep 2014 New trial record